



EmphyCorp is the First Ever Rx Nonsteroidal Bronchodilator Nasal Spray with no Adverse Effects that Reduces or Eliminates the Rate and Severity of Coughing in Patients with Chronic Coughing and Uncontrolled Coughing

Flemington, NJ – November 19, 2025 - EmphyCorp Inc. www.EmphyCorp.com a private corporation, with several De-Risked late-stage patented drugs for a Non-Steroidal Bronchodilator Nasal Spray Drugs that **simultaneously treats several medical endpoints including Chronic Coughing, Uncontrolled Coughing, Low Oxygen, Shortness of Breath, Fatigue and by increasing the synthesis of Nitric Oxide, kills viruses, bacteria, and fungi in the nasal passages.** To date, Emphycorp has successful completed (24) human Clinical Studies which include Phase 2 and Phase 3 Clinical Trials for Interstitial Lung Disease (Pulmonary Fibrosis with COPD, Idiopathic Pulmonary Fibrosis-IPF Coughing and Improved Lung Function, CF), Core Respiratory Diseases (COPD, Asthma), Allergic Rhinitis, Sinusitis, Long COVID, Flu, and COVID-19 treatments. EmphyCorp has Orphan Drug Designation for all Interstitial Lung Diseases.

Rx N115 Nonsteroidal Nasal Spray significantly reduces or eliminates coughing by eliminating nasal infections, irritants, inflammation, and inflammatory cytokines that stimulate the Vagus nerve receptors to produce the cough reflex. Coughing is a reflex triggered by signals sent along the Vagus nerve. Stimulated cough receptors (RARS and C-fiber receptors) in the airway send impulses through the Vagus nerve to the brainstem, which then sends signals backdown through the Vagus nerve to muscles to produce the cough. Rapidly adapting receptors (RARS respond to these irritants causing bronchoconstriction. N115 reduces or eliminates coughing and increases bronchodilation.

N115 Nonsteroidal Nasal Spray produced clinically and statically significant increases for all lung functions including bronchodilation and decreased coughing in 2,334 patients representing 24 Phase 2/3 Clinical Trials, in patients with moderate and severe COPD, Allergic rhinitis, Cystic Fibrosis, Long COVID, COVID, Flu, and patients with Interstitial lung Diseases (Pulmonary Fibrosis, IPF, CF). Patented *Rx N115 Nasal Spray also increases Nasal Nitric Oxide which prevents and reduces the rate and severity of viral infections from the Common Cold, Rhinoviruses, Flu and Coronavirus, which increases the cough reflex.*

Phase 3 Clinical Trial with Rx N115 Nonsteroidal Nasal Spray for IPF Coughing (73% reduction, all Patients with Uncontrolled Coughing were finally able to sleep at night) and Improved Lung Function (Hypoxemia and Dyspnea)

In a Pivotal Phase 3, Double Blinded, Randomized Placebo-Controlled study with the EmphyCorp Bronchodilator Rx Nonsteroidal Nasal Spray with no adverse events reported for **Coughing (73% reduction; All Patients with Uncontrolled Coughing were finally able to sleep at night)** and Improved Lung Function (Hypoxemia and Dyspnea) was performed in patients with Idiopathic Pulmonary Fibrosis (IPF) for the NDA Application in which Coughing was significantly reduced as was Bronchoconstriction.

In this Phase 3 Clinical Trial for IPF Coughing, 70% of these patients suffer from Sinusitis, which produces mucus and biofilms. The data from this study demonstrated that **Coughing episodes per 24 hours were significantly reduced with no exceptions in all N115 treated patients by 38.4% on day 14 and by 73.2% on 22 day of the trial,** whereas the placebo treated group reduced coughing by 16.1% on day 22 (p< 0.0001).

This correlated well with increased FEV1/FVC ratio, which was 27.9% on day 22 with N115 treated patients compared to 2.37% for placebo (p< 0.0001). In N115 treated patients at week 2 showed a significant 26.6% improvement in FEV-1 values compared to 6.83% in the placebo group (p=0.0004).).

After day 21, patients discontinued use of the study medication. Patients were contacted by phone for follow up after 3 months. Impressively, patients reported reduced coughing for a mean 38.8 days for N115 compared to only 5.54 days for the placebo (p<0.0001).

Prior Phase 2 Placebo Controlled Clinical Trial with Rx N115 Nonsteroidal Nasal Spray for Pulmonary Fibrosis with COPD and Idiopathic Pulmonary Fibrosis met several Medical Endpoints including Coughing

EmphyCorp Bronchodilator Rx N115 Nonsteroidal Nasal Spray with no adverse events reported demonstrated a statistically and clinically significant increase in FEV-1, SaO2, FVC, FEV-1/FVC ratios (52% to 86%), and a clinically significant **reduction in coughing (p= 0.0001)**, reduction in nasal inflammation, congestion and clinically significant increase in nasal nitric oxide. Nasal inflammation and congestion block the release of nasal nitric oxide. Blockage of nitric oxide increases the rate and severity of infections. **Phase 3 Clinical Trial for COPD in 2026.**

Phase 2 Placebo Controlled Clinical Trial with Rx N115 Nonsteroidal Nasal Spray for Long COVID

It is estimated there are 20 million patients with Long COVID that suffer from trouble breathing, hypoxemia, dyspnea, coughing, and fatigue with approximately 10% worldwide who develop Pulmonary Fibrosis and IPF (2 million patients). **In EmphyCorp Bronchodilator Rx N115 Nonsteroidal Nasal Spray treated Long COVID patients, no adverse events were reported and a significant improvement ($p<0.0043$) in coughing/sneezing and improvement in trouble breathing ($p<0.0003$) were recorded.** Headaches were also reduced significantly ($p=0.036$). Immediately after the first dose of Rx N115 Nasal Spray was administered, in as little as 15 minutes, SaO₂ improved significantly ($p<0.0008$) and continued to improve by day 14 ($p<0.0001$). The increase in SaO₂ and increased lung functions demonstrated decreased hypoxemia and dyspnea. N115 also showed some improvements with anxiety, loss of taste/smell, congestion, and body aches.

Phase 3 Clinical Trial for Long COVID in 2026.

True Innovation in Treating Patients with Coughing and Respiratory Diseases that Provides a better “Quality of Life” for Patients with Chronic Coughing, Interstitial Lung Diseases (PF, IPF, CF), Moderate and Severe COPD, Asthma, Long COVID, Flu, Allergic Rhinitis, Sarcoidosis, Sinusitis, Congestion, and other Serious Respiratory Diseases without the use of albuterol, steroids, and anti-mucosal drugs and their side effects

Unlike other drug research approaches to combining multiple older Albuterol, Steroid, and Anti-Mucosal Drugs or combining bronchodilators in combination with anti-inflammatory drugs or agents that block inflammatory pathways (PDE3 and PDE4 inhibitors), for treating Interstitial Lung Diseases, COPD, and other respiratory conditions that have serious side effects, **Patented Rx N115 Bronchodilator Nonsteroidal Nasal Spray with no adverse effects utilizes a single Nasal Spray to increase the synthesis of Nasal Nitric Oxide to increase bronchodilation and decrease Chronic Coughing in patients with Interstitial Lung Diseases, COPD, Asthma, Long COVID, and other respiratory conditions that also kills invading bacteria, fungi, and viruses to prevent infections, in addition to eliminating inflammatory cytokines (including the cytokine storm), and also eliminating oxygen radicals to produced clinically and statistically significant improvement in all lung functions including FEV-1, FVC, FEV-1/FVC Ratios thus eliminating Hypoxemia, Dyspnea and smokers cough. EmphyCorp has (8) Drug Patents including (3) new Composition Patents for the treatment of all lung and sinus diseases including one for “Apoptosis of Myofibroblasts” to slow/stop lung fibrosis.**

In a recently completed successful Pivotal Randomized Double Blinded Placebo Controlled Phase III Clinical Trial in patients with Idiopathic Pulmonary Fibrosis (IPF) Coughing (73% reduction) and Improved Lung Function (Hypoxemia and Dyspnea) with our Rx N115 Nonsteroidal Nasal Spray with no adverse events reported, produced a clinically and statistically significant decrease in coughing and improved lung function, while allowing all patients with Uncontrolled Coughing to sleep at night.

Note: Diabetic and Hypertensives should not use Steroid Sprays because they are counter-indicated with the use of drugs taken for Diabetes and High Blood Pressure. Rx N115 Nonsteroidal Nasal Sprays have been shown to be safe in (24) Respiratory Clinical Studies to date including for the treatment of COPD and Severe COPD.

Dr. Alain Martin (CEO) created the EmphyCorp Patented Bronchodilator Rx Nonsteroidal Nasal Sprays with no side effects, as well as Advanced Neosporin, Advanced Lubriderm, Early Pregnancy Test (EPT), Cool Mint Listerine, plus discovering the use of Rx Rezulin Drug for Type II Diabetes earlier in his career at Warner Lambert (Pfizer acquisition). He also created patented OTC and Rx products including next generation triple antibiotic, skincare, drug free post laser aftercare lotion with a cooling gel for pain, patented pet anxiety product (OTC or Rx) with no side effects for our sister company North Cell Pharmaceutical www.NorthCellPharma.com.

An Up-to-date Rx N115 Nasal Spray Drug Pipeline, Peer Reviews, and Press Releases can be found on the EmphyCorp website www.EmphyCorp.com.

Please contact Robert Millar for more information and Partnership interest at 973-586-4421 or EmphyCorp@optonline.net.
